

Special Issue

Sepsis Management and Antibiotic Therapy

Message from the Guest Editor

Sepsis is a severe medical condition that requires urgent attention and prompt treatment. It occurs when the body's immune system overreacts to an infection, leading to inflammation and damage to tissues and organs. Sepsis can quickly progress into septic shock, which can be life-threatening. Antibiotic therapy is a critical component of sepsis management, helping to kill bacteria causing infection and prevent its spread throughout the body. However, the overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, which pose a significant challenge to sepsis management. This Special Issue aims to provide an overview of the current best practices in Sepsis Management and Antibiotic Therapy, publishing the latest research, guidelines, and clinical recommendations. Submissions to this issue should include topics such as the use of biomarkers for sepsis management, the role of antimicrobial stewardship in preventing antibiotic resistance, and emerging therapies for sepsis treatment.

Guest Editor

Prof. Dr. Egidia Gabriela Miftode

1. Department of Internal Medicine II, Faculty of Medicine, University of Medicine and Pharmacy Gr. T. Popa, 700115 Iași, Romania
2. "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iași, Romania

Deadline for manuscript submissions

closed (31 July 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/186266

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)